schizophrenia

News

BMS says it will set Cobenfy's UK price the same as the US

Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.

News

Heather Turner, LB Pharma's chief executive.

After a long biotech IPO lull, LB Pharma chances its arm

After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

News

Click, Boehringer DTx for schizophrenia passes phase 3 test

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

Has trial result burst BMS' Cobenfy bubble?

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

News

Schizophrenia highlighted in a list of definitions of disorders

Advantage BMS as AbbVie drug fails schizophrenia trials

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

BMS says it will set Cobenfy's UK price the same as the US

After a long biotech IPO lull, LB Pharma chances its arm

Click, Boehringer DTx for schizophrenia passes phase 3 test

Has trial result burst BMS' Cobenfy bubble?

Boehringer drug for brain fog in schizophrenia fails trial

Advantage BMS as AbbVie drug fails schizophrenia trials

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

schizophrenia

Editor's Picks